Month: August 2020

NEODESHA, Kan., Aug. 17, 2020 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE American: UAVS) (“AgEagle or the “Company”), an industry leading provider of UAVs and advanced aerial imagery, data collection and analytics solutions, today announced its second quarter financial results for the three and six months ended June 30, 2020.Key Financial HighlightsRevenue increased 516% to $408,000 from $66,000 for the six-month comparable periods in 2020 and 2019. For the three months ended June 30, 2020, revenue was $16,000 compared to $20,000 for the same three months in the prior year. This decline was primarily due to the impact of COVID-19 on AgEagle’s supply chain, resulting in the delivery delay of certain parts needed for the manufacturing and assembly of drones and related drone package delivery equipment. Approximately $770,000...

WOBURN, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited trait C3007 in canola plant lines developed for increased oil content.  Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website.  In June 2020, Yield10 submitted an “Am I regulated?” letter to the BRS, requesting confirmation of the regulatory status for canola plant lines containing the Company’s novel, CRISPR genome-edited C3007 trait. The positive USDA-APHIS response came in the form of a published letter indicating that the plant lines do not meet the definition of a regulated article under 7 CFR Part 340 regulations. Confirmation...

BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, before the U.S. financial markets open. Entera’s management will host a conference call on Thursday, August 20, 2020 at 8:30 a.m. EDT to discuss the results for the quarter. A question-and-answer session will follow Entera’s remarks. To participate on the live call, please dial (855) 547-3865 (US) or (409) 217-8787 (international) and provide the conference ID “5243229” five to ten minutes before the start of the call.To access a live audio webcast of the presentation on the “Investor Relations” page of Entera’s website, please click here. A replay of the webcast...

UNIONDALE and ISLANDIA, N.Y., Aug. 17, 2020 (GLOBE NEWSWIRE) — Today, John R. Buran, President and Chief Executive Officer of Flushing Financial Corporation (“Flushing”) (Nasdaq-GS:FFIC) announced, “I am pleased that our respective Boards have agreed to extend the timeframe for Flushing to complete the acquisition of Empire Bancorp Inc. (“Empire”) (OTC:EMPK), and we are now anticipating a fourth quarter close.“With this acquisition, we will create a community bank of superior scale and operational leverage that presents us with a greater ability to improve service to our customers and enhance shareholder value. The acquisition of Empire is consistent with our stated strategic objectives. This acquisition will reduce our cost of funds and increase our non-interest bearing deposits. It will make us more efficient in both the short...

TAMPA, Fla., Aug. 17, 2020 (GLOBE NEWSWIRE) — Odyssey Marine Exploration, Inc. (NASDAQ:OMEX), a deep-ocean exploration pioneer engaged in the discovery, development and extraction of deep-ocean minerals, reported results for the second quarter ended June 30, 2020, and provided an update on current company operations and projects.Odyssey’s key focus during the quarter continued to be the Exploraciones Oceanicas (ExO) phosphate project in Mexico. This project could provide access to a critical resource needed to produce fertilizer, helping to provide food security to the Mexican people and supplying the phosphate needs of North America for at least 50 years.Odyssey’s legal teams are working two separate, but concurrent processes, while Odyssey continues to work through diplomatic channels in attempts to reach a mutually beneficial...

FDA sets target action date of June 1, 2021BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids has been accepted for review by the U.S. Food and Drug Administration (FDA).“Relugolix is now under FDA review for two distinct potential new treatment options in uterine fibroids and advanced prostate cancer, indications with high unmet need where we have the opportunity to elevate the standard of care for women and for men,” said Lynn Seely, M.D., chief executive officer of Myovant...

Company Aims to Expand its Footprint to International Markets on the African ContinentNEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), a technology company engaged in providing smart security solutions and developing education-related technologies in China, has, through one of its variable interest entities, entered into a Cooperation Framework Agreement with China Africa Friendship Town Investment Group Limited (“CAFTI”) to establish a general framework and promote Datasea’s products across several countries in Africa.As a Ugandan-based and registered limited company, CAFTI specializes in industrial park investments and construction, IT services, as well as import and export trades across Africa, and has developed a network of contacts across the continent, including, Uganda,...

LONDON, Aug. 17, 2020 (GLOBE NEWSWIRE) — Horizonte Minerals Plc (the “Company” or “Horizonte”) (AIM: HZM; TSX: HZM), the nickel development company focused in Brazil, is pleased to announce that it has today published its 2019 Sustainability Report. The report is an overview of the Company’s sustainability performance over the 2019 financial year and is primarily focussed on the Araguaia ferronickel project but, data from the Vermelho nickel-cobalt project and corporate head office is included where appropriate.The report is available to view on the Company’s website at: https://horizonteminerals.com/uk/en/sustainability_report/This is the first standalone Sustainability Report that Horizonte has published as the Company recognises the importance of conveying its efforts and achievements around the areas of environmental...

NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or “Company”) (CSE: ACRG.U) (OTCQX: ACRGF) (FSE: 0VZ) today announces its intention to amend the term and exercise price of the 6,085,192 Class A subordinate voting share purchase warrants (the “Warrants”) issued as part of the Company’s private placement which closed on February 10, 2020.Under the current terms, each Warrant can be exercised to acquire one Class A subordinate voting share of Acreage (each, a “Warrant Share”) until 4:00 p.m. on February 10, 2025 at an exercise price of US$5.80 per Warrant Share. Subject to all conditions to the Amended Arrangement (as hereinafter defined) being satisfied (to the extent capable of being satisfied at the relevant time), the Company intends to modify the exercise price of the Warrants to US$4.00 per Warrant...

SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the clearance of the pivotal ENVASARC protocol after filing the protocol with the U.S. Food and Drug Administration (FDA) as part of an Investigational New Drug (IND) application on July 15. The application cross referenced the open envafolimab IND maintained by TRACON’s corporate partners 3D Medicines and Alphamab Oncology. TRACON expects to initiate enrollment in the ENVASARC trial at 25 sites in the U.S. in the fourth quarter of 2020.“We...